Last reviewed · How we verify
Erlotinib, standard dose
Erlotinib is a tyrosine kinase inhibitor that targets the epidermal growth factor receptor (EGFR) tyrosine kinase.
Erlotinib is a tyrosine kinase inhibitor that targets the epidermal growth factor receptor (EGFR) tyrosine kinase. Used for Non-small cell lung cancer, Pancreatic cancer.
At a glance
| Generic name | Erlotinib, standard dose |
|---|---|
| Also known as | Tarceva |
| Sponsor | Hoffmann-La Roche |
| Drug class | EGFR tyrosine kinase inhibitor |
| Target | EGFR |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
By inhibiting the EGFR tyrosine kinase, erlotinib prevents the activation of downstream signaling pathways that promote cell proliferation and survival. This leads to the inhibition of tumor growth and induction of apoptosis in cancer cells. Erlotinib is particularly effective in tumors with EGFR mutations or overexpression.
Approved indications
- Non-small cell lung cancer
- Pancreatic cancer
Common side effects
- Rash
- Diarrhea
- Fatigue
- Nausea
- Vomiting
- Anorexia
- Dyspnea
- Cough
- Pneumonitis
- Interstitial lung disease
Key clinical trials
- Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma (PHASE2)
- AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (PHASE3)
- A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886) (PHASE1)
- First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) Metastases (PHASE2, PHASE3)
- Phase Ib Study of Erlotinib Prior to Surgery in Patients With Head and Neck Cancer (PHASE1)
- Intravenous Vitamin C in Combination With Standard Chemotherapy for Pancreatic Cancer (PHASE1)
- Erlotinib (Tarceva) During First Line Standard Platinum Containing Chemo for Advanced Squamous Cell Head and Neck Cancer (PHASE2, PHASE3)
- A Study of BGB324 (Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Erlotinib, standard dose CI brief — competitive landscape report
- Erlotinib, standard dose updates RSS · CI watch RSS
- Hoffmann-La Roche portfolio CI